Stocks · News reference

Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug

Aug 20, 2026, 1:25 PMVandana Singh

Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP patients.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

The Motley FoolAug 21, 2026, 11:02 AMAndy Gould
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?
The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.
Read original at the-motley-fool
AMGN VRTX REGN
BenzingaAug 20, 2026, 10:33 AMRadhika Anilkumar Nadig
Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain Hemorrhage
Bill Ackman gifted $400 million of his Pershing Square stake to a brain research foundation after his daughter's near-fatal hemorrhage.
Read original at benzinga
PS REGN
BenzingaAug 19, 2026, 6:02 PMBenzinga Newsdesk
Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO)
Read original at benzinga
REGN